Hoffmann-La Roche

ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO

Retrieved on: 
Friday, October 28, 2022
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Vall d'Hebron University Hospital, ImmunoGen, Company, Security (finance), U.S. Securities and Exchange Commission, Carboplatin, European Society for Medical Oncology, MD, AE, Cancer, Progression-free survival, Congress, BLA, Patient, Senior, Physician, European Society of Gynaecological Oncology, ISS, Cleavage, Program, DOR, Annual report, ETB, PFS, Industry, IMGN, Toxicity, Genta (company), COVID-19, Woman, Hoffmann-La Roche, AES, Review, ORR, ESGO, Immunohistochemistry, FDA, IHC, EBT, Ovarian cancer, Control, Financial toxicity, PDUFA, IST, ADC, Pharmaceutical industry, Gasoline, Fine chemical, Genentech

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced findings from a retrospective pooled analysis of patients who achieved extended treatment benefit (ETB) with mirvetuximab soravtansine (mirvetuximab) monotherapy across three clinical trials in folate receptor alpha (FR)positive recurrent ovarian cancer.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced findings from a retrospective pooled analysis of patients who achieved extended treatment benefit (ETB) with mirvetuximab soravtansine (mirvetuximab) monotherapy across three clinical trials in folate receptor alpha (FR)positive recurrent ovarian cancer.
  • These findings were highlighted in a poster presentation at the 23rd Congress of the European Society of Gynaecological Oncology (ESGO) in Berlin, Germany.
  • In a pooled analysis of 466 patients, mirvetuximab monotherapy demonstrated ETB in 40 patients (9%).
  • ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

The Galien Foundation Honors 2022 Prix Galien Award Recipients

Retrieved on: 
Friday, October 28, 2022
University, Health, Bill & Melinda Gates Foundation, Bill, Columbia University Irving Medical Center, Life, Disease, American Cancer Society, CEO, Perseverance, List of Nobel laureates, Physiology, Protein, Human Genome Sciences, P. Roy Vagelos, Medical genetics, Fred Hutchinson Cancer Research Center, Digital health, Hoffmann-La Roche, University of Washington, Science, Kavli Foundation (United States), Gene, Former, Pharmaceutical industry, Biophysics, Incubator

NEW YORK, Oct. 28, 2022 /PRNewswire/ -- The Prix Galien USA Committee honored excellence and innovation in life sciences during the Prix Galien USA Forum and 16th annual Prix Galien Awards Gala last night at the American Museum of Natural History in New York City. The USA Committee, composed of 10 renowned leaders from the biomedical industry and academia, including two Nobel Laureates, honored winners in the following categories: "Best Biotechnology Product," "Best Pharmaceutical Agent," "Best Medical Technology," "Best Digital Health Solution," "Incubators, Accelerators and Equity," and "Prix Galien Startup."

Key Points: 
  • "On behalf of the Prix Galien USA Awards Committee, we thank all nominees and winners for their continued ingenuity and perseverance in the advancement of science, healthcare, and wellness, globally," said Dr. Sue Desmond-Hellmann, Chair of the Prix Galien USA and Prix Galien International Award Committees and former CEO of the Bill & Melinda Gates Foundation.
  • "The Prix Galien Awards exist to celebrate and recognize the immense efforts and achievements of its participants, which has been truly demonstrated by this year's distinguished cohort."
  • "The nominees and winners of the Prix Galien Awards represent the very best in modern scientific discovery and innovation.
  • "The Prix Galien Awards have a long history of recognizing the best products in biopharmaceutical and medical technology, with industry leaders carefully evaluating nominees and selecting the most impactful innovators," said Bruno Cohen, Chairman of The Galien Foundation.

Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit

Retrieved on: 
Wednesday, October 26, 2022
DNA, Safety, Cancer, VB, Risk, Squamous cell carcinoma, Immunotherapy, Fatigue, Papilloma, Patient, Uncertainty, Technology, Diarrhea, ELISpot, B cell, Protein, Cervical cancer, Adaptation, Oslo Stock Exchange, Partnership, Immune system, Toxicity, Nature, HPV, GLOBE, NSCLC, APC, COVID-19, Infection, CD8, Hoffmann-La Roche, Therapy, OSE, Roche, Head, Neck, Regeneron Pharmaceuticals, ASA, Vaccine, Pharmaceutical industry, Genentech

The data will be presented today at the Neoantigen-Based Therapies Summit in Boston, Massachusetts.

Key Points: 
  • The data will be presented today at the Neoantigen-Based Therapies Summit in Boston, Massachusetts.
  • The data continue to substantiate our differentiated platform technology and support its huge potential within individualized cancer treatments.
  • Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases.
  • A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Aurion Biotech Wins Prestigious Prix Galien Startup Award

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Optical, Health, Wyeth, Ophthalmology, Endothelial dysfunction, Fortune 1000, CEO, The Hills Have Eyes 2, Endothelium, Physician, Alcon, Transplant, Paganini Competition, Patient, Petrichor, Multimedia, Cornea, Corneal transplantation, Digital health, Hoffmann-La Roche, Medicine, Former, Nobel Prize, Health, Pharmaceutical industry, Biotechnology, Incubator

Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has won the prestigious Prix Galien Award for Best Startup in Biotech / Pharma.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has won the prestigious Prix Galien Award for Best Startup in Biotech / Pharma.
  • Aurion Biotech received the Best Start-up in Biotech / Pharma award, one of six different award categories, and was chosen from more than 146 products from 129 nominee companies, spanning 14 therapeutic areas.
  • The vetting process was rigorous: nominees are invited to apply for the Prix Galien award.
  • According to the Galien Foundation, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

BioNTech to Report Third Quarter 2022 Financial Results and Operational Update on November 7, 2022

Retrieved on: 
Monday, October 24, 2022
BNTX, Hoffmann-La Roche, BioNTech, Geneve 9640, RNA transfection, Telephone, Investor relations, Webcast, Nasdaq, Cancer, Infection, Company, CEST, Immunotherapy, EDT, GLOBE, Regeneron Pharmaceuticals, Pfizer, Genentech

Mainz, Germany, October 24, 2022 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) will announce its financial results for the third quarter 2022 on Monday, November 7th, 2022.

Key Points: 
  • Mainz, Germany, October 24, 2022 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) will announce its financial results for the third quarter 2022 on Monday, November 7th, 2022.
  • BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the third quarter 2022.
  • To access the live conference call via telephone, please register via this link .
  • The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.

Early Treatment With Genentech’s Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile

Retrieved on: 
Wednesday, October 26, 2022
Neurology, Biotechnology, Pharmaceutical, General Health, Health, Hospitals, Clinical Trials, Other Health, Hoffmann-La Roche, Congress, Disease, MS, DMT, Multiple sclerosis, RRMS, RO, Family, Pregnancy, Patient, NEDA, HIV disease progression rates, EDSS, MRI, Treatment, PPMS, Disability, ROG, Research, RMS, Safety, ARR, Database, European Committee of the Regions, Pharmaceutical industry, Medical imaging, Genentech

The majority of patients had no relapses (93%), no MRI lesion activity (89%) and no 24-week confirmed disability progression (91%).

Key Points: 
  • The majority of patients had no relapses (93%), no MRI lesion activity (89%) and no 24-week confirmed disability progression (91%).
  • The safety profile of Ocrevus in this trial was consistent with its overall favorable safety profile.
  • Additionally, patients treated with first-line Ocrevus had lower hospitalization rates within one year compared with patients treated with second-line or later Ocrevus (0.02 vs. 0.042, respectively).
  • Tell your healthcare provider if you have had an allergic reaction to Ocrevus or any of its ingredients in the past.

Inotrem Announces That Its ESSENTIAL Phase II Study for the Treatment of Critically ill COVID-19 Patients Meets Its Primary and Key Secondary Endpoints

Retrieved on: 
Tuesday, October 25, 2022
Health, Infectious Diseases, Other Health, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Capacity, Hoffmann-La Roche, Disease, Immunomodulation, Septic shock, Nancy, PRIME, EMA, Infection, COVID, Particle-size distribution, Critical care, Patient, COVID 19, Standard of care, Investor, Research, Investment, Mortality, Length of stay, European Society for Medical Oncology, Senior, Intensive care medicine, Capacity building, CEO, Independent Board for Presbyterian Foreign Missions, Immunotherapy, Survival, Clinical trial, Inflammation, National, Nangibotide, FDA, COVID-19, PIA, Myocardial infarction, Pharmaceutical industry, ICU

Nangibotide treatment also showed a statistically and clinically meaningful 12% absolute and 43% relative reduction in Day 28 mortality (key secondary endpoint) in the overall trial population (p value = 0.030).

Key Points: 
  • Nangibotide treatment also showed a statistically and clinically meaningful 12% absolute and 43% relative reduction in Day 28 mortality (key secondary endpoint) in the overall trial population (p value = 0.030).
  • The data we obtained is extremely encouraging, and we plan on quickly consulting regulatory authorities in the US and EU.
  • In parallel, Inotrem has also launched an antibody-based program to develop a new therapeutic modality targeting chronic inflammatory diseases.
  • Inotrem is supported by leading European and North American investors Inotrem is part of the French Tech 120, a government program dedicated to support the development of fast-growing startups.

Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022

Retrieved on: 
Wednesday, October 19, 2022
RNA transfection, Pharmacist, National, Walter, Society of Infectious Diseases Pharmacists, Infectious Diseases Society of America, DNA, Solution, Epidemiology, Enactment, NYSE, MPH, Makerere University, Private Securities Litigation Reform Act, Company, JN-International Medical Corporation, LNC, PIDS, Cryptococcosis, GLOBE, Consultant, Hoffmann-La Roche, Amikacin, Infectious Diseases Institute, Diagnosis, Vaccine, Boulware, Walter E. Washington Convention Center, Research, Gilead Sciences, Technology, BioNTech, HIV, Organic acid, IDSA, Form 10-K, Washington Convention Center, Risk, Sale, SEC, Society, Patient, Infection, Partnership, Forward-looking statement, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery, Genentech, MD

Atukunda and Boulware will present the EnACT Phase 2 abstract on Friday, October 21st at the Walter E. Washington Convention Center, in Washington DC.

Key Points: 
  • Atukunda and Boulware will present the EnACT Phase 2 abstract on Friday, October 21st at the Walter E. Washington Convention Center, in Washington DC.
  • IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP).
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022

Retrieved on: 
Wednesday, October 19, 2022
Biotechnology, Pharmaceutical, Health, People, Hoffmann-La Roche, Union, Colon, Birth, Time, Breast milk, Infection, Medicine, Risk, Inflammation, Woman, Vaccine, Patient, IL-6, Recycling, Genentech, Allergy, Hepatitis B, Hepatitis B virus, Immune system, Neutrophil, Disability, Cancer, Health, Antibody, Blood, Breast cancer, Vaccination, Vitamin, Fever, Phase, Colitis, FDA, Pregnancy, Conditional sentence, Breakthrough therapy, Health insurance, Pharmaceutical industry, Birth control, Dietary supplement, Risk management, Liquor, Satralizumab, Ocrelizumab, NMOSD

You should receive any required live or live-attenuated vaccines at least 4 weeks before you start treatment with Ocrevus.

Key Points: 
  • You should receive any required live or live-attenuated vaccines at least 4 weeks before you start treatment with Ocrevus.
  • When possible, you should receive any non-live vaccines at least 2 weeks before you start treatment with Ocrevus.
  • You should use birth control (contraception) during treatment with Ocrevus and for 6 months after your last infusion of Ocrevus.
  • Talk with your healthcare provider about what birth control method is right for you during this time.

Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Retrieved on: 
Thursday, October 13, 2022
LinkedIn, U.S. Securities and Exchange Commission, BioNTech, Hoffmann-La Roche, Pierre Geneves, Omicron, RNA transfection, Risk, SEC, Science, YouTube, Vaccine, Peer review, Pfizer–BioNTech COVID-19 vaccine, Research, Twitter, Publication, Program, Facebook, Cancer, Private Securities Litigation Reform Act, Infection, Emergency Use Authorization, Company, Marketing, Form, Awareness, Pediatrics, Safety, Ageing, Immunotherapy, News, Clinical trial, COVID-19, Regeneron Pharmaceuticals, Pfizer, BNT162, Genentech

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • In addition, to learn more, please visit us on and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.